Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13866139 | 0.90 | NPC1 (0.33) | NPC1KDM4E | |
| SCHEMBL13866135 | 0.85 | NPC1 (0.39) | NPC1KDM4EMEN1KMT2AMAP4K1 | |
| SCHEMBL13866137 | 0.84 | ALDH1A1 (0.36) | NPC1KDM4EMEN1KMT2AMAP4K1 | |
| SCHEMBL13866116 | 0.82 | NPC1 (0.41) | NPC1KDM4EMAP4K1 | |
| SCHEMBL13866115 | 0.81 | CFTR (0.39) | NPC1KDM4EHTTSMN1; SMN2 | |
| SCHEMBL13866140 | 0.81 | NPC1 (0.34) | NPC1 | |
| SCHEMBL13865869 | 0.80 | ALDH1A1 (0.38) | NPC1KDM4EHTTSMN1; SMN2MAP4K1 | |
| SCHEMBL13870973 | 0.80 | NPC1 (0.37) | NPC1 | |
| SCHEMBL5667295 | 0.80 | CFTR (0.43) | NPC1KDM4E | |
| SCHEMBL13866141 | 0.77 | L3MBTL1 (0.30) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137597-A1 | Novel quinoxalinone derivatives | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-7388010-B2 | Quinoxalinone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137597-A1 | Novel quinoxalinone derivatives | NDUFB1, NDUFB6, NDUFB7 | NPC1 1218/4885KDM4E 2867/4885MEN1 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.